

Remarks

Claims 24-26, 29-36 and 38 were pending in the subject application. By this Amendment, the applicants have amended claims 24-26, 29, 30, 36 and 38. No new subject matter has been added by this amendment. Accordingly, claims 24-26, 29-36, and 38 are now pending and before the Examiner for consideration.

The amendments set forth herein should not be interpreted to indicate that the applicants have agreed with, or acquiesced to, the rejections set forth in the outstanding Office Action. The amendments to the claims have been made in an effort to lend greater clarity to the claimed subject matter and to expedite prosecution. Favorable consideration of the claims now presented, in view of the remarks and amendment set forth herein, is earnestly solicited.

Claims 24-26, 29-36 and 38 have been rejected under 35 U.S.C. §112, first paragraph as being non-enabled. The applicants believe that the claims as previously presented were fully enabled; however, in order to expedite prosecution, by this Amendment, the applicants have deleted reference to the term “solvate” in the claims, thereby rendering moot this ground for rejection. Accordingly, the applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. §112, first paragraph.

Claims 36 and 38 have been rejected under 35 U.S.C. §112, first paragraph. The Office Action indicates that the claims are enabled for inhibition of HIV-1. Therefore, in order to expedite prosecution, by this Amendment, claim 36 has been amended to refer to inhibition of HIV-1. Accordingly, the applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. §112, first paragraph.

In view of the foregoing remarks and the amendments above, the applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

The applicants also invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephone interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,

A handwritten signature in black ink, reading "David Saliwanchik". The signature is fluid and cursive, with the first name "David" and last name "Saliwanchik" clearly distinguishable.

David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

DRS/la